DK0806948T3 - Behandling af urininkontinens ved anvendelse af (S)-oxybutynin og (S)-desethyloxybutynin - Google Patents

Behandling af urininkontinens ved anvendelse af (S)-oxybutynin og (S)-desethyloxybutynin

Info

Publication number: DK0806948T3
Authority: DK; Denmark
Prior art keywords: desethyloxybutynin; oxybutynin; urinary incontinence; treatment; disclosed
Prior art date: 1995-01-31

Application number

DK96906202T

Other languages

Danish (da)

English (en)

Inventor

Gunnar Aberg

Cullough John R Mc

Yue Fang

Original Assignee

Sepracor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-01-31

Filing date

1996-01-25

Publication date

2000-12-18

1995-01-31 Priority claimed from US08/381,542 external-priority patent/US5532278A/en

1996-01-25 Application filed by Sepracor Inc filed Critical Sepracor Inc

2000-12-18 Application granted granted Critical

2000-12-18 Publication of DK0806948T3 publication Critical patent/DK0806948T3/da

Links

SNIBJKHIKIIGPR-HXUWFJFHSA-N 4-(ethylamino)but-2-ynyl (2s)-2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C1([C@@](O)(C(=O)OCC#CCNCC)C=2C=CC=CC=2)CCCCC1 SNIBJKHIKIIGPR-HXUWFJFHSA-N 0.000 title abstract 3
206010046543 Urinary incontinence Diseases 0.000 title abstract 2
SWIJYDAEGSIQPZ-VZYDHVRKSA-N esoxybutynin chloride Chemical compound Cl.C1([C@@](O)(C(=O)OCC#CCN(CC)CC)C=2C=CC=CC=2)CCCCC1 SWIJYDAEGSIQPZ-VZYDHVRKSA-N 0.000 title 1
XIQVNETUBQGFHX-JOCHJYFZSA-N esoxybutynin Chemical compound C1([C@@](O)(C(=O)OCC#CCN(CC)CC)C=2C=CC=CC=2)CCCCC1 XIQVNETUBQGFHX-JOCHJYFZSA-N 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 abstract 1
SNIBJKHIKIIGPR-UHFFFAOYSA-N N-desethyloxybutynin Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCNCC)C1CCCCC1 SNIBJKHIKIIGPR-UHFFFAOYSA-N 0.000 abstract 1
230000002411 adverse Effects 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229960005434 oxybutynin Drugs 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Urology & Nephrology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK96906202T 1995-01-31 1996-01-25 Behandling af urininkontinens ved anvendelse af (S)-oxybutynin og (S)-desethyloxybutynin DK0806948T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/381,542 US5532278A (en)	1995-01-31	1995-01-31	Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US08/480,194 US5677346A (en)	1995-01-31	1995-06-07	Treating urinary incontinence using (S)-desethyloxybutynin
PCT/US1996/001053 WO1996023492A1 (en)	1995-01-31	1996-01-25	Treating urinary incontinence using (s)-oxybutynin and (s)-desethyloxybutynin

Publications (1)

Publication Number	Publication Date
DK0806948T3 true DK0806948T3 (da)	2000-12-18

Family

ID=27009434

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK96906202T DK0806948T3 (da)	1995-01-31	1996-01-25	Behandling af urininkontinens ved anvendelse af (S)-oxybutynin og (S)-desethyloxybutynin

Country Status (24)

Country	Link
US (1)	US5677346A (de)
EP (1)	EP0806948B1 (de)
JP (1)	JPH11511730A (de)
KR (1)	KR100390271B1 (de)
CN (1)	CN1151786C (de)
AT (1)	ATE196252T1 (de)
AU (1)	AU706741B2 (de)
BR (1)	BR9607001A (de)
CA (1)	CA2211400C (de)
CZ (1)	CZ290093B6 (de)
DE (1)	DE69610290T2 (de)
DK (1)	DK0806948T3 (de)
ES (1)	ES2150663T3 (de)
FI (1)	FI973163A7 (de)
GR (1)	GR3034974T3 (de)
HU (1)	HUP9800794A3 (de)
NO (1)	NO315927B1 (de)
NZ (1)	NZ303372A (de)
PL (1)	PL182768B1 (de)
PT (1)	PT806948E (de)
RU (1)	RU2181589C2 (de)
SK (1)	SK283313B6 (de)
UA (1)	UA45387C2 (de)
WO (1)	WO1996023492A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5736577A (en) *	1995-01-31	1998-04-07	Sepracor, Inc.	Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US6171298B1 (en)	1996-05-03	2001-01-09	Situs Corporation	Intravesical infuser
WO1998011888A1 (en) *	1996-09-19	1998-03-26	American Home Products Corporation	Method of treating urinary incontinence
US6123961A (en) *	1996-09-25	2000-09-26	Bridge Pharma, Inc.	Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
AU2018299A (en) *	1997-12-31	1999-07-19	Sepracor, Inc.	(s)-procyclidine for treating urinary incontinence
US6183461B1 (en)	1998-03-11	2001-02-06	Situs Corporation	Method for delivering a medication
US6013830A (en) *	1998-03-30	2000-01-11	Sepracor Inc.	Asymmetric grignard synthesis with cyclic 1,2 aminoalcohols
DE69942928D1 (de) *	1998-08-27	2010-12-23	Pfizer Health Ab	Therapeutische formulierung zur verabreichung von tolterodin mit kontrollierter freisetzung
AU767877B2 (en) *	1999-05-20	2003-11-27	Sepracor, Inc.	Methods for treatment of asthma using S-oxybutynin
US6432446B2 (en) *	2000-02-03	2002-08-13	Bridge Pharma, Inc.	Non-arrhythmogenic metabolite of oxybutynin
US6521724B2 (en)	2000-03-10	2003-02-18	E. I. Du Pont De Nemours And Company	Polymerization process
US6436428B1 (en)	2000-03-21	2002-08-20	Enhance Pharmaceuticals, Inc.	Device and method for treating urinary incontinence in females
US7029694B2 (en)	2000-04-26	2006-04-18	Watson Laboratories, Inc.	Compositions and methods for transdermal oxybutynin therapy
US20030124177A1 (en) *	2000-04-26	2003-07-03	Watson Pharmaceuticals, Inc.	Compositions and methods for transdermal oxybutynin therapy
CN101843601A (zh) *	2000-04-26	2010-09-29	沃特森药物公司	最小化与奥昔布宁疗法有关的副作用
US7179483B2 (en) *	2000-04-26	2007-02-20	Watson Pharmaceuticals, Inc.	Compositions and methods for transdermal oxybutynin therapy
JP5684964B2 (ja) *	2000-06-07	2015-03-18	ワトソンファーマシューティカルズ，インコーポレイテッド	（ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
US8980290B2 (en)	2000-08-03	2015-03-17	Antares Pharma Ipl Ag	Transdermal compositions for anticholinergic agents
ATE485837T1 (de) *	2000-08-03	2010-11-15	Antares Pharma Ipl Ag	Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
US7198801B2 (en)	2000-08-03	2007-04-03	Antares Pharma Ipl Ag	Formulations for transdermal or transmucosal application
DE10041478A1 (de)	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung
DE10060550C1 (de) *	2000-12-06	2002-04-18	Lohmann Therapie Syst Lts	Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
DE10103262A1 (de) *	2001-01-25	2002-08-01	Axel Schmidt-Dossi	Arzneimittel gegen Blasenfunktionsstörung
WO2002062389A1 (en)	2001-02-08	2002-08-15	Ono Pharmaceutical Co., Ltd.	Remedies for urinary diseases comprising lpa receptor controlling agents
WO2002076426A2 (en) *	2001-03-27	2002-10-03	Galen (Chemicals) Limited	Intravaginal drug delivery devices for the administration of an antimicrobial agent
US20030027856A1 (en) *	2001-06-29	2003-02-06	Aberg A.K. Gunnar	Tolterodine metabolites
MXPA04003806A (es) *	2001-11-05	2005-04-08	Upjohn Co	Aerosol antimuscarinico.
US20030185882A1 (en) *	2001-11-06	2003-10-02	Vergez Juan A.	Pharmaceutical compositions containing oxybutynin
US7921999B1 (en)	2001-12-20	2011-04-12	Watson Laboratories, Inc.	Peelable pouch for transdermal patch and method for packaging
JP2005516992A (ja) *	2001-12-21	2005-06-09	ブリッジファーマ、インコーポレイテッド	オキシブチニンの非心律動異常惹起性代謝物
ES2239196T3 (es) *	2002-12-02	2005-09-16	Schwarz Pharma Ag	Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
RU2241442C1 (ru) *	2003-09-17	2004-12-10	Научный центр акушерства, гинекологии и перинатологии РАМН	Вагинальные суппозитории для лечения императивного недержания мочеиспускания
ATE534373T1 (de)	2003-10-10	2011-12-15	Antares Pharma Ipl Ag	Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
US7425340B2 (en) *	2004-05-07	2008-09-16	Antares Pharma Ipl Ag	Permeation enhancing compositions for anticholinergic agents
US8067399B2 (en)	2005-05-27	2011-11-29	Antares Pharma Ipl Ag	Method and apparatus for transdermal or transmucosal application of testosterone
CN101426475A (zh)	2006-04-21	2009-05-06	安塔雷斯制药Ipl股份公司	使用用于经皮或经粘膜应用的制剂治疗热潮红的方法
US9119777B2 (en)	2008-05-30	2015-09-01	Microdose Therapeutx, Inc.	Methods and compositions for administration of oxybutynin
BRPI0812000A2 (pt) *	2007-05-30	2014-11-18	Microdose Therapeutx Inc	Métodos e composições para administração de oxibutinina
US8415390B2 (en)	2008-05-30	2013-04-09	Microdose Therapeutx, Inc.	Methods and compositions for administration of oxybutynin
US8920392B2 (en)	2009-05-05	2014-12-30	Watson Laboratories, Inc.	Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
AU2011285928B9 (en)	2010-08-03	2018-08-02	B3Ar Therapeutics, Inc.	Combinations of beta - 3 adrenergic receptor agonists and muscarinic receptor antagonists for treating overactive bladder
US9907767B2 (en)	2010-08-03	2018-03-06	Velicept Therapeutics, Inc.	Pharmaceutical compositions and the treatment of overactive bladder
TW201338772A (zh)	2012-02-09	2013-10-01	Altherx Inc	藥學組合物
JP2012176958A (ja) *	2012-04-20	2012-09-13	Watson Pharmaceuticals Inc	（ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
US20160151321A1 (en)	2012-11-13	2016-06-02	Dinesh C. Patel	Methods for the treatment of sialorrhea
US20140135392A1 (en) *	2012-11-13	2014-05-15	NeuRx Pharmaceuticals LLC	Methods for the treatment of sialorrhea
CN104116760A (zh) *	2014-07-14	2014-10-29	玉庆花	一种治疗遗尿的口服液
HK1245117A1 (zh)	2014-12-03	2018-08-24	Velicept Therapeutics, Inc.	使用调节释放索拉贝隆用於下尿路症状的组合物和方法
ES2967863T3 (es)	2015-10-23	2024-05-06	B3Ar Therapeutics Inc	Ion dipolar de solabegron y usos del mismo

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL124473C (de) *	1960-07-26
BE902605A (fr) *	1985-06-06	1985-09-30	Therabel Res S A N V	Composition pharmaceutique utilisable dans le traitement des maladies des voies urinaires, son procede de preparation et methode d'utilisation de cette composition.
MX9202350A (es) *	1991-05-20	1992-11-01	Alza Corp	Composiciones de incrementador de penetracion a la piel que usan monolinoleato de glicerol.
JP3066515B2 (ja) *	1992-11-11	2000-07-17	久光製薬株式会社	尿失禁治療用経皮投与製剤
JP3688293B2 (ja) *	1993-09-29	2005-08-24	アルザ・コーポレーション	モノグリセリド／乳酸エステル透過促進剤

1995
- 1995-06-07 US US08/480,194 patent/US5677346A/en not_active Expired - Fee Related
1996
- 1996-01-25 NZ NZ303372A patent/NZ303372A/xx unknown
- 1996-01-25 WO PCT/US1996/001053 patent/WO1996023492A1/en not_active Ceased
- 1996-01-25 PT PT96906202T patent/PT806948E/pt unknown
- 1996-01-25 CZ CZ19972421A patent/CZ290093B6/cs not_active IP Right Cessation
- 1996-01-25 DE DE69610290T patent/DE69610290T2/de not_active Expired - Fee Related
- 1996-01-25 PL PL96321498A patent/PL182768B1/pl not_active IP Right Cessation
- 1996-01-25 BR BR9607001A patent/BR9607001A/pt not_active IP Right Cessation
- 1996-01-25 ES ES96906202T patent/ES2150663T3/es not_active Expired - Lifetime
- 1996-01-25 AT AT96906202T patent/ATE196252T1/de not_active IP Right Cessation
- 1996-01-25 SK SK1035-97A patent/SK283313B6/sk unknown
- 1996-01-25 EP EP96906202A patent/EP0806948B1/de not_active Expired - Lifetime
- 1996-01-25 JP JP8523636A patent/JPH11511730A/ja not_active Ceased
- 1996-01-25 CN CNB961928891A patent/CN1151786C/zh not_active Expired - Fee Related
- 1996-01-25 UA UA97084420A patent/UA45387C2/uk unknown
- 1996-01-25 DK DK96906202T patent/DK0806948T3/da active
- 1996-01-25 FI FI973163A patent/FI973163A7/fi not_active IP Right Cessation
- 1996-01-25 KR KR1019970705184A patent/KR100390271B1/ko not_active Expired - Fee Related
- 1996-01-25 AU AU49664/96A patent/AU706741B2/en not_active Ceased
- 1996-01-25 HU HU9800794A patent/HUP9800794A3/hu unknown
- 1996-01-25 RU RU97114572/14A patent/RU2181589C2/ru not_active IP Right Cessation
- 1996-01-25 CA CA002211400A patent/CA2211400C/en not_active Expired - Fee Related
1997
- 1997-07-30 NO NO19973516A patent/NO315927B1/no unknown
2000
- 2000-11-24 GR GR20000402596T patent/GR3034974T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
MX9705820A (es)	1997-10-31
JPH11511730A (ja)	1999-10-12
EP0806948B1 (de)	2000-09-13
FI973163A0 (fi)	1997-07-30
PL182768B1 (pl)	2002-02-28
KR100390271B1 (ko)	2003-10-04
CZ242197A3 (en)	1997-12-17
RU2181589C2 (ru)	2002-04-27
ATE196252T1 (de)	2000-09-15
WO1996023492A1 (en)	1996-08-08
NO315927B1 (no)	2003-11-17
UA45387C2 (uk)	2002-04-15
EP0806948A1 (de)	1997-11-19
AU4966496A (en)	1996-08-21
GR3034974T3 (en)	2001-02-28
NO973516D0 (no)	1997-07-30
US5677346A (en)	1997-10-14
SK283313B6 (sk)	2003-05-02
HUP9800794A3 (en)	1999-05-28
AU706741B2 (en)	1999-06-24
CA2211400A1 (en)	1996-08-08
HK1017986A1 (en)	1999-12-10
BR9607001A (pt)	1997-10-28
CN1151786C (zh)	2004-06-02
FI973163L (fi)	1997-09-30
NO973516L (no)	1997-08-07
FI973163A7 (fi)	1997-09-30
HUP9800794A2 (hu)	1998-07-28
ES2150663T3 (es)	2000-12-01
PT806948E (pt)	2001-02-28
PL321498A1 (en)	1997-12-08
NZ303372A (en)	1999-01-28
CN1179714A (zh)	1998-04-22
SK103597A3 (en)	1999-03-12
CA2211400C (en)	2007-01-23
DE69610290T2 (de)	2001-03-29
CZ290093B6 (cs)	2002-05-15
DE69610290D1 (de)	2000-10-19

Publication	Publication Date	Title
DK0806948T3 (da)	2000-12-18	Behandling af urininkontinens ved anvendelse af (S)-oxybutynin og (S)-desethyloxybutynin
CA2257121A1 (en)	1998-01-08	Methods and compositions for treating urinary incontinence using optically pure (s)-oxybutynin
NO20002172L (no)	2000-07-04	FremgangsmÕte for behandling av hyperkolesterolemi med usubstituert polydiallylamin
RU2011138835A (ru)	2013-03-27	Применение производного рапамицина
CA2180535A1 (en)	1995-07-13	A method for treatment of psoriasis, by omeprazole or related compounds
NO179250C (no)	1996-09-04	Analogifremgangsmåte for fremstilling av terapeutisk aktiv (+)--(2,3-dimetoksyfenyl)-1-[2-(4-fluorfenyl)etylÅ-4-piperidinmetanol
DK0867179T3 (da)	2000-11-06	Sammensætning af L-DOPA-estere
AU7578894A (en)	1995-05-04	Methods for inhibiting smooth muscle cell proliferation and restinosis
DK0869808T3 (da)	2006-11-13	Anvendelse af Glu-Trp-dipeptider til fremstilling af et lægemiddel til behandling af forskellige tilstande, der involverer neovaskularisation
MY129473A (en)	2007-04-30	3,3-diarylpropylamines, their use and preparation
BR9813767A (pt)	2000-10-03	Processo e composição para tratar glaucoma de glc1a
MY119375A (en)	2005-05-31	Treatment of tinnitus using neuroprotective agents
NO20000093L (no)	2000-03-10	(+)-Norcisaprid nyttig for 5-HT3 og 5-HT4-medierte forstyrrelser
DE69328838D1 (de)	2000-07-13	Antipyretische und analgetische verfahren und zusammensetzungen, die optisch reines r-etodolac enthalten
ATE225177T1 (de)	2002-10-15	Verwendung von (+)mefloquine zur behandlung von malaria
NO984920D0 (no)	1998-10-22	Sammensetninger omfattende en nitroneforbindelse for anvendelse ved behandling av okulµr inflammasjon
GEP20012511B (en)	2001-08-27	Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
WO2001000187A3 (en)	2001-11-15	Pharmaceutical composition containing sibutramine and a lipase inhibitor
MY133438A (en)	2007-11-30	Morpholinobenzamide salts
WO1999033454A3 (en)	1999-10-21	S-procyclidine for treating urinary incontinence
WO2000076490A3 (en)	2002-03-21	Methods and compositions for treating urinary frequency and urgency using optically pure (s)-oxybutynin
WO1999033453A3 (en)	1999-10-07	R-procyclidine for treating urinary incontinence
TW218014B (en)	1993-12-21	A new therapeutically active compound
MY110416A (en)	1998-05-30	Composition for the treatment of schizophrenia.
MX9704887A (es)	1998-06-30	Composiciones farmaceuticas para el tratamiento de trastornos depresivos.